Jubilant Pharmova Ltd

Jubilant Pharmova Limited has announced the closure of its trading window for dealing in the company's securities. This closure is effective from October 1, 2026, and will remain in effect until 48 hours after the declaration of the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The company has informed all Designated Persons and their Immediate Relatives about this restriction, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The exact date of the board meeting to approve these financial results will be communicated separately. The information will also be available on the company's website.

Jubilant Pharmova Ltd has announced that the final dividend for the financial year 2025-26 has been withheld for shareholders who have not submitted the required Know Your Customer (KYC) documents. This action is in compliance with SEBI Master Circular HO/38/13/(4)2026-MIRSD-POD/I/4298/2026 dated February 6, 2026, which mandates electronic dividend payments and updated KYC particulars for physical security holders. Shareholders are required to submit updated KYC details, including PAN, address, bank account, and specimen signature, along with specific forms like ISR-1, ISR-2, and SH-13/ISR-3, to the company's Registrar & Share Transfer Agent (RTA) to receive their withheld dividend.

Jubilant Pharmova Limited announced that its subsidiary, Jubilant HollisterStier LLC's contract manufacturing organization (CMO) facility in Spokane, Washington, USA, has been classified as 'Voluntary Action Indicated' (VAI) by the USFDA. This classification follows the USFDA's review of the Establishment Inspection Report (EIR) for the inspection conducted between June 8-17, 2026. The VAI classification indicates that while the inspection identified some observations, they do not warrant a more severe regulatory action at this time. Jubilant HollisterStier is a key player in manufacturing sterile injectables and ophthalmics.

Jubilant Pharmova Limited has received a Show Cause Notice from the Assistant Commissioner of Commercial Taxes (Enforcement)-4, Mysore, proposing a demand of ₹87.31 Crore. This includes GST (₹33.58 Cr), interest (₹20.15 Cr), and penalty (₹33.58 Cr) for the Financial Year 2022-2023. The notice cites issues such as alleged ineligible ITC, excess ITC availed, and differential tax liability based on E-waybill records. The company is preparing a detailed reply to contest the demand, asserting that the notice is factually and legally incorrect and was issued without proper verification. Jubilant Pharmova expects no financial or operational impact as they believe they have a strong case.

Jubilant Pharmova's wholly-owned subsidiary, Jubilant Generics Limited, has received a Show Cause Notice from the Joint Commissioner, CGST Division, Roorkee. The notice proposes a demand of ₹52.75 Cr for GST, an equal amount for penalty, and an unquantified amount for interest. This pertains to the financial years 2020-21 and 2021-2022, alleging the simultaneous availment of IGST refund and the benefit of the Advance Authorisation scheme, in violation of CGST Rules. Jubilant Pharmova states the notice is factually and legally incorrect and expects no financial or operational impact, as they have a strong case and will file a detailed reply.

Jubilant Pharmova Limited announced that its subsidiary, Jubilant HollisterStier LLC (JHS), has received USFDA approval for commercial batch manufacturing on Line 3 of its contract manufacturing facility in Spokane, USA. This new Isolator-based fill and finish line will be used for the first product's commercial production. JHS is a key contract manufacturer of sterile injectables and ophthalmics, serving the pharmaceutical and biopharmaceutical industries. This approval signifies an expansion of JHS's capabilities and its role in supplying regulated markets.

Jubilant Pharmova reported Q1 FY27 results with revenue increasing 17% year-on-year to ₹2,229 Cr, driven by strong growth across all business segments, particularly CDMO Sterile Injectables. However, EBITDA saw an 11% decline to ₹268 Cr and PAT fell 45% to ₹56 Cr, mainly due to the unavailability of high-margin SPECT radiopharmaceutical products and increased operating expenses. The company expects EBITDA margins to improve from H2 FY27 as SPECT products become available. Key segments like Radiopharma and Radiopharmacy showed revenue growth, with significant investments planned for PET manufacturing network expansion. Progress was also noted in Allergy Immunotherapy, CDMO, Generics, and Proprietary Novel drugs businesses.

Consolidated revenue rose 17.3% YoY to ₹2,229.4 Cr, in line with (slightly ahead of) the ₹2,100-2,200 Cr range flagged in our pre-result preview and matching management's own "solid growth of 17% on YoY basis" framing. But consolidated PAT fell 45.0% YoY and 52.7% QoQ to ₹56.4 Cr, well short of the ₹70-90 Cr PAT range the preview had set as the bar. Since neither this quarter nor the year-ago quarter carried exceptional items (Q4 FY26, by contrast, had a ₹13.7 Cr exceptional item), the decline is a clean operational one, not a one-off swing. EPS came in at ₹3.57 versus ₹6.49 a year ago and ₹7.55 last quarter. EBITDA, per management, was ₹268 Cr for the quarter — an implied margin of ~12.0%, down from ~15.2% a year ago and ~14.2% last quarter, missing the preview's 15-16% expectation. Management attributes this to the unavailability of high-margin SPECT radiopharmaceutical products, which shows up directly in the segment data: Radiopharma segment profit fell to ₹78.0 Cr from ₹98.6 Cr YoY even though segment revenue grew to ₹1,022.1 Cr from ₹868.6 Cr. The sharper margin hit sits in CDMO Sterile Injectables, exactly the segment management called out as a growth driver: revenue there jumped 32.4% YoY to ₹519.8 Cr on technology-transfer income from the new/third line, but segment profit collapsed to ₹7.3 Cr from ₹43.1 Cr — the new capacity is adding revenue but diluting margins, the Montreal-related capacity question the Street was watching into this print. Jubilant Pharmova gives no formal quarterly guidance on record, so this print is judged against Street's implicit bar rather than a company target — on that basis it is a revenue beat but a clear profit and margin miss. The tax-rectification tailwind flagged as a pre-result watch item did not materialise this quarter: the effective tax rate held near 34.7% (₹30.0 Cr tax on ₹86.4 Cr PBT), close to last year's 33.6%. On the corporate calendar, the board meeting was pushed from Aug 5 to Aug 10 to finalise these results, and the company has an AGM scheduled for Aug 26 alongside the FY26 dividend payout — neither bears on this quarter's operating numbers. Standalone, a much smaller slice of the group, posted PAT of ₹7.3 Cr on revenue of ₹67.1 Cr, EPS ₹0.46.

Jubilant Pharmova Ltd announced that its Board of Directors met on August 10, 2026, to approve the unaudited financial results for the quarter ended June 30, 2026. The results, both standalone and consolidated, along with the limited review report, have been submitted. These documents will also be available on the company's official website. The meeting concluded after reviewing these financial statements.

Jubilant Pharmova Ltd has informed BSE that its Board of Directors meeting, originally scheduled for August 7, 2026, has been postponed due to unavoidable circumstances. The meeting will now be held on August 10, 2026. The primary agenda remains the consideration and approval of the Un-audited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The trading window for company securities will remain closed until August 12, 2026, for designated persons and their immediate relatives.